By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Head Office
Technologielaan 3
Leuven    B - 3001  Belgium
Phone: 32-16-39-60-60 Fax: 32-16-39-60-70



Company News
TiGenix Release: Convening Notice To The Annual Shareholders' Meeting To Be Held On 2 June 2016 5/3/2016 8:40:54 AM
TiGenix Selects TFS For The First Clinical Trial To Treat Severe Sepsis With Allogeneic Expanded Adipose-Derived Stem Cells 4/19/2016 9:06:33 AM
TiGenix Presents 24 Week Results Of Its Cx601 Phase III Trial At ECCO 2016 3/18/2016 9:03:35 AM
TiGenix Announces Positive 52-Week Phase III Results Of Cx601 In Complex Perianal Fistulas In Crohn's Disease Patients 3/7/2016 12:38:25 PM
TiGenix Submits MAA To European Medicines Agency For Cx601 For The Treatment Of Complex Perianal Fistulas In Crohn's Disease Patients 3/2/2016 3:49:25 PM
TiGenix Obtains Commercial Production License For Cx601 2/23/2016 9:17:58 AM
TiGenix Announces Acceptance Of Cx601 Abstract For Presentation At ECCO 2016 Congress 1/11/2016 9:28:39 AM
TiGenix Participates In Key Conferences In The First Half Of 2016 1/8/2016 10:16:34 AM
TiGenix Publishes Transparency Notification Pursuant To Article 14 Of The Law Of May 2, 2007 12/29/2015 8:32:24 AM
TiGenix Files Registration Statement For Proposed U.S. IPO 12/23/2015 10:11:53 AM